Adial Pharmaceuticals (ADIL) Equity Average (2022 - 2024)
Adial Pharmaceuticals' Equity Average history spans 3 years, with the latest figure at $5.1 million for Q3 2024.
- For Q3 2024, Equity Average rose 79.63% year-over-year to $5.1 million; the TTM value through Sep 2024 reached $5.1 million, up 79.63%, while the annual FY2023 figure was $3.7 million, N/A changed from the prior year.
- Equity Average for Q3 2024 was $5.1 million at Adial Pharmaceuticals, down from $5.2 million in the prior quarter.
- Across five years, Equity Average topped out at $9.3 million in Q2 2022 and bottomed at $2.4 million in Q1 2023.
- The 3-year median for Equity Average is $4.7 million (2022), against an average of $4.7 million.
- The largest annual shift saw Equity Average plummeted 74.52% in 2023 before it skyrocketed 118.59% in 2024.
- A 3-year view of Equity Average shows it stood at $4.3 million in 2022, then fell by 26.05% to $3.2 million in 2023, then soared by 58.19% to $5.1 million in 2024.
- Per Business Quant, the three most recent readings for ADIL's Equity Average are $5.1 million (Q3 2024), $5.2 million (Q2 2024), and $5.1 million (Q1 2024).